A Phase 1 interventional study of Bimekizumab in Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis, sponsored by UCB Biopharma SRL. Recruiting at 14 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.
Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 13th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 1, and was the 13th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 210 across the 14 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 5 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 17 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
18 studies in Arthritis, Psoriatic by UCB S.A.: 2 open now, 3 under way, 1 of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 18 studies in Arthritis, Psoriatic by UCB S.A., this one is the 16th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 1, and was the 17th registered.
UCB S.A.’s Arthritis, Psoriatic studies by the year they started, since 2010.
1 of the studies testing bimekizumab in Arthritis, Psoriatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 18 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Breastfeeding mothers who are already receiving commercial bimekizumab per locally approved prescribing information and in consultation and agreement with their treating physicians will participate in this study. Study participants will continue receiving commercially available bimekizumab under the care of their treating physician.
Drug: Bimekizumab
Bimekizumab under the care of their treating physician.
Also known as: Bimzelx®
Concentration of bimekizumab in the breast milk on Day 1
Breast milk samples will be collected predose on Day 1.
Time frame: Day 1
Concentration of bimekizumab in the breast milk on Day 2
Breast milk samples will be collected predose on Day 2.
Time frame: Day 2
Concentration of bimekizumab in the breast milk on Day 3
Breast milk samples will be collected predose on Day 3.
Time frame: Day 3
Concentration of bimekizumab in the breast milk on Day 5
Breast milk samples will be collected predose on Day 5.
Time frame: Day 5
Concentration of bimekizumab in the breast milk on Day 7
Breast milk samples will be collected predose on Day 7.
Time frame: Day 7
Concentration of bimekizumab in the breast milk on Day 9
Breast milk samples will be collected predose on Day 9.
Time frame: Day 9
Concentration of bimekizumab in the breast milk on Day 11
Breast milk samples will be collected predose on Day 11.
Time frame: Day 11
Concentration of bimekizumab in the breast milk on Day 13
Breast milk samples will be collected predose on Day 13.
Time frame: Day 13
Concentration of bimekizumab in the breast milk on Day 15
Breast milk samples will be collected predose on Day 15.
Time frame: Day 15
Concentration of bimekizumab in the breast milk on Day 29
Breast milk samples will be collected predose on Day 29 for mothers on every 4 weeks (Q4W) dosing regimen.
Time frame: Day 29
Concentration of bimekizumab in the breast milk on Day 57
Breast milk samples will be collected predose on Day 57 for mothers on every 8 weeks (Q8W) dosing regimen.
Time frame: Day 57
Estimated Infant Dosage of bimekizumab from breast milk
Breast milk samples will be collected predose on Day 1 (bimekizumab dosing day), Days 2, 3, 5, 7, 9, 11, 13, and 15 for all study participants (Day 15 predose if every 2 weeks (Q2W) dosing regimen), predose on Day 29 (if Q4W dosing regimen) or Day 57 (if Q8W dosing regimen).
Time frame: Predose on Day 1, 2, 3, 5, 7, 9, 11, 13, 15, 29 and 57
Relative Infant Dose of bimekizumab from breast milk
Breast milk samples will be collected predose on Day 1 (bimekizumab dosing day), Days 2, 3, 5, 7, 9, 11, 13, and 15 for all study participants (Day 15 predose if every 2 weeks (Q2W) dosing regimen), predose on Day 29 (if Q4W dosing regimen) or Day 57 (if Q8W dosing regimen).
Time frame: Predose on Day 1, 2, 3, 5, 7, 9, 11, 13, 15, 29 and 57
Treatment-emergent Adverse Events (TEAEs) of the mother from time of informed consent through SFU contact
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.
Time frame: From time of informed consent up to approximately 17 weeks
Plan to share: No — Due to the small sample size in this trial, individual patient-level data cannot be adequately anonymized as there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.
Of 15 phase 1 interventional studies under Arthritis, Psoriatic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 35. This study's planned 25 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab